https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50456 2 cm (4.5%) or grade 3 tumors (5.5%). These sustained reductions of the risk of recurrence with adjuvant exemestane + OFS, compared with tamoxifen + OFS, provide guidance for selecting patients for whom exemestane should be preferred over tamoxifen in the setting of OFS.]]> Wed 28 Feb 2024 15:10:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32778 Wed 07 Feb 2024 16:54:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47747 Tue 21 Mar 2023 19:00:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29018 P = .14) and in triple-negative (TN) disease (n = 814; HR, 0.80; 95% CI, 0.60 to 1.06). Patients with TN, node-positive disease had a nonstatistically significant reduced HR (n = 340; HR, 0.72; 95% CI, 0.49 to 1.05). Seventy-one (13%) of 542 patients assigned to CM maintenance did not start CM. Of 473 patients who received at least one CM maintenance dose (including two patients assigned to no CM), 64 (14%) experienced a grade 3 or 4 treatment-related adverse event; elevated serum transaminases was the most frequently reported (7%), followed by leukopenia (2%). Conclusion: CM maintenance did not produce a significant reduction in DFS events in hormone receptor-negative early breast cancer. The trend toward benefit observed in the TN, node-positive subgroup supports additional exploration of this strategy in the TN, higher-risk population.]]> Sat 24 Mar 2018 07:31:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27579 Sat 24 Mar 2018 07:23:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23908 Sat 24 Mar 2018 07:10:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29891 Fri 01 Apr 2022 09:22:24 AEDT ]]>